Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C10H12FNO3 |
| Molecular Weight | 212.2081 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
N[C@H](CC1=CC=C(OC[18F])C=C1)C(O)=O
InChI
InChIKey=GEBHVOHKNWLITQ-DEVVULMSSA-N
InChI=1S/C10H12FNO3/c11-6-15-8-3-1-7(2-4-8)5-9(12)10(13)14/h1-4,9H,5-6,12H2,(H,13,14)/t9-/m1/s1/i11-1
| Molecular Formula | C10H12FNO3 |
| Molecular Weight | 212.2081 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
BAY-86-9596 (D-18F-FMT, or O-18F-fluoromethyl-D-tyrosine) was developed as an agent not only for tumor detection but also for monitoring early-phase response to radiation therapy by positron emission tomography (PET). This drug participated in clinical trials for patients with inflammation and solid tumors, but further information about trials is not available.
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 10:14:07 GMT 2023
by
admin
on
Sat Dec 16 10:14:07 GMT 2023
|
| Record UNII |
58HVN5SR99
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DB15296
Created by
admin on Sat Dec 16 10:14:07 GMT 2023 , Edited by admin on Sat Dec 16 10:14:07 GMT 2023
|
PRIMARY | |||
|
870452-26-9
Created by
admin on Sat Dec 16 10:14:07 GMT 2023 , Edited by admin on Sat Dec 16 10:14:07 GMT 2023
|
PRIMARY | |||
|
11579379
Created by
admin on Sat Dec 16 10:14:07 GMT 2023 , Edited by admin on Sat Dec 16 10:14:07 GMT 2023
|
PRIMARY | |||
|
300000041416
Created by
admin on Sat Dec 16 10:14:07 GMT 2023 , Edited by admin on Sat Dec 16 10:14:07 GMT 2023
|
PRIMARY | |||
|
58HVN5SR99
Created by
admin on Sat Dec 16 10:14:07 GMT 2023 , Edited by admin on Sat Dec 16 10:14:07 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Results: No adverse reactions were observed related to D-18F-FMT. Fifty-two lesions were 18F-FDGpositive, and 42 of
those were malignant (34 histologically proven and 8 with clinical reference). Thirty-two of the 42 malignant lesions were also D-18FFMT positive, and 10 lesions had no tracer uptake above the level of the blood pool. Overall there were 34 true-positive, 8 true-negative, 10 false-negative, and only 2 false-positive lesions for D-18FFMT,
whereas 18F-FDG was true-positive in 42 lesions, with 10 false-positive and only 2 false-negative, resulting in a lesion-based detection rate for D-18F-FMT and 18F-FDG of 77% and 95%, respectively, with an accuracy of 78% for both tracers. A high D-18F-FMT tumor-to-blood pool ratio had a negative correlation with overall survival (P 5 0.050), whereas the 18F-FDG tumor-to-blood pool ratio did not correlate with overall survival.
|
||
|
ACTIVE MOIETY |
Originator: Bayer HealthCare Pharmaceuticals; Class: Imaging agent, Radioisotope, Radiopharmaceutical diagnostic, Radiopharmaceutical; Mechanism of Action: Ionising radiation emitter, Positron-emission tomography enhancer; Orphan Drug Status: No; On Fast track: No; New Molecular Entity: No; Available For Licensing: Yes; Highest Development Phases: Phase I for Inflammation, Solid tumour; Most Recent Events: 13 Nov 2014 BAY 869596 is available for licensing as of 13 Nov 2014. http://piramal.com/piramal-enterprises/piramal-capital, 13 Nov 2014 Phase I development is ongoing in Switzerland, Netherlands and Singapore
|
